Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Somogyi (Heidelberg, Germany), M. Eichinger (Heidelberg, Germany), F. Lasitschka (Heidelberg, Germany), J. Kappes (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany). Interstitial lung disease in CVID (GLILD): clinical presentation and comparison to CVID without ILD. 1409

Member's Comments

No comment yet.

Related content which might interest you: Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003 Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Are there any clinical differences between SSc-ILD and UCTD suspected of SSc -ILD? Source: International Congress 2015 – Connective tissue disorders Year: 2015 Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia Source: International Congress 2017 – Lung function testing Year: 2017 Pattern and impact of rheumatology referral in patients with ILD and autoimmune features Source: International Congress 2016 – Connective tissue disorders Year: 2016 Clinical characteristics of patients with unclassifiable interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Myositis-associated interstitial pneumonia (MaIP): Autoantibody associations in patients presenting to pulmonologists and rheumatologists Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Clinical characteristics of anti-Jo-1-positive interstitial lung disease Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 ERS guidelines on treatment of sarcoidosis Source: ERS webinar 2021: ERS guidelines on treatment of sarcoidosis Year: 2021 The prevalence and subtypes of interstitial lung disease in polymyositis and dermatomyositis patients Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Characterization of interstitial pneumonia associated with clinical amyopathic dermatomyositis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Clinical features of interstitial lung disease in polymyositis and dermatomyositis Source: Eur Respir J 2006; 28: Suppl. 50, 828s Year: 2006 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Delay in diagnosis of interstitial lung diseases (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Mortality and clinical features in rheumatoid arthritis and interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017